Biologics and airway remodeling in severe asthma

G Varricchi, S Ferri, J Pepys, R Poto, G Spadaro… - Allergy, 2022 - Wiley Online Library
Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in
part can become irreversible to conventional therapies, defining the concept of airway …

The role of lung and gut microbiota in the pathology of asthma

W Barcik, RCT Boutin, M Sokolowska, BB Finlay - Immunity, 2020 - cell.com
Asthma is a common chronic respiratory disease affecting more than 300 million people
worldwide. Clinical features of asthma and its immunological and molecular etiology vary …

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

ME Wechsler, LB Ford, JF Maspero… - The Lancet …, 2022 - thelancet.com
Background Clinical trials have shown treatment benefits of dupilumab in patients with
uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and …

EAACI Biologicals Guidelines—Recommendations for severe asthma

I Agache, CA Akdis, M Akdis, GW Canonica, T Casale… - Allergy, 2021 - Wiley Online Library
Severe asthma imposes a significant burden on patients, families and healthcare systems.
Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care …

Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial

EL Simpson, AS Paller, EC Siegfried… - JAMA …, 2020 - jamanetwork.com
Importance Adolescents with atopic dermatitis (AD) have high disease burden negatively
affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a …

Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets

C Pelaia, E Heffler, C Crimi, A Maglio… - Frontiers in …, 2022 - frontiersin.org
Interleukins (IL)-4 and-13 play a pivotal role in the pathobiology of type-2 asthma. Indeed, IL-
4 is crucially involved in Th2 cell differentiation, immunoglobulin (Ig) class switching and …

Molecular targets for biological therapies of severe asthma

C Pelaia, C Crimi, A Vatrella, C Tinello… - Frontiers in …, 2020 - frontiersin.org
Asthma is a heterogeneous respiratory disease characterized by usually reversible
bronchial obstruction, which is clinically expressed by different phenotypes driven by …

New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis

I Striz, K Golebski, Z Strizova, S Loukides… - Clinical …, 2023 - portlandpress.com
Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) or without (CRSsNP) are
chronic respiratory diseases. These two disorders often co-exist based on common …

[HTML][HTML] Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions

J Oppenheimer, FCL Hoyte, W Phipatanakul… - Annals of Allergy …, 2022 - Elsevier
Objective Severe asthma is associated with substantial personal and economic burden;
maintaining disease control is the key management goal. Increased understanding of …

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines …

I Agache, C Rocha, J Beltran, Y Song, M Posso, I Solà… - Allergy, 2020 - Wiley Online Library
Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are
increased, with some degree of overlap with other phenotypes. Systematic reviews …